In short
Belvarafenib is an emerging drug being studied in clinical trials for its potential in treating various types of cancer. This article explores the ongoing research on belvarafenib, focusing on its use in patients with specific genetic mutations and its potential to improve outcomes for those with advanced or metastatic solid tumors.
At a glance
- Drug Name
- Belvarafenib
- Administration
- Oral, 400 mg twice daily (BID)
- Target Populations
- Patients with NRAS-mutant advanced melanoma, BRAF class II mutant/fusion-positive tumors, BRAF class III mutant-positive tumors
- Study Designs
- Phase Ib, open-label, multicenter studies; Part of larger platform trials
- Primary Outcomes
- Safety, tolerability, pharmacokinetics, anti-tumor activity
- Secondary Outcomes
- Objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS)
- Combination Therapies
- Studied alone and in combination with cobimetinib or cobimetinib plus nivolumab
- Patient Age Groups
- Adults and adolescents ≥ 40 kg
What is belvarafenib?
Belvarafenib is a new drug being studied for the treatment of various types of cancer, particularly advanced melanoma and other solid tumors. It belongs to a class of drugs known as targeted therapies, which are designed to attack specific cancer cells while minimizing damage to healthy cells.
How Does Belvarafenib Work?
Belvarafenib works by targeting specific genetic mutations in cancer cells. It is particularly effective against tumors with BRAF mutations. BRAF is a gene that, when mutated, can cause cells to grow and divide uncontrollably, leading to cancer. Belvarafenib is designed to block the effects of these mutated BRAF genes, potentially slowing or stopping the growth of cancer cells.
What Conditions Does Belvarafenib Treat?
Belvarafenib is being studied for the treatment of several types of cancer, including:
- Advanced Melanoma: This is a serious form of skin cancer that has spread to other parts of the body. Belvarafenib is being tested in patients with NRAS-mutant advanced melanoma who have previously received immunotherapy.
- BRAF Class II Mutant or Fusion-Positive Tumors: These are tumors with specific genetic changes in the BRAF gene.
- BRAF Class III Mutant-Positive Tumors: Another type of tumor with a different BRAF gene mutation.
- Other Solid Tumors: Belvarafenib is also being studied in various other types of solid tumors that have specific genetic mutations.
Ongoing Clinical Trials
Belvarafenib is currently being studied in several clinical trials:
- NCT04835805: This study is evaluating belvarafenib alone and in combination with other drugs (cobimetinib and nivolumab) in patients with advanced melanoma. The trial aims to determine the safety and effectiveness of these treatments.
- TAPISTRY Platform Study (NCT04589845): This is a larger study looking at various targeted therapies, including belvarafenib, for different types of solid tumors with specific genetic mutations.
How is Belvarafenib Administered?
Belvarafenib is taken orally (by mouth) in the form of tablets or capsules. In the clinical trials, it is typically administered as follows:
- For adults and adolescents weighing 40 kg or more: 400 mg twice a day (BID)
- It should be taken with adequate water (more than 200 mL)
- One treatment cycle usually consists of 28 days
- Belvarafenib is taken every day of each 28-day cycle
Potential Side Effects
As with all medications, belvarafenib may cause side effects. The full range of side effects is still being studied in clinical trials. Common side effects of targeted therapies like belvarafenib may include:
- Fatigue
- Skin rashes
- Digestive issues (nausea, diarrhea)
- Changes in appetite
It's important to note that the safety profile of belvarafenib is still being evaluated in clinical trials. Patients participating in these trials are closely monitored for any adverse events.
